Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus casei BL23
- Development stage
- Preclinical
- Lead developer
- INRAE
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus casei BL23 (recently reclassified as Lacticaseibacillus casei BL23) is a non-pathogenic, Gram-positive probiotic bacterium belonging to the lactic acid bacteria group. It is widely utilized in biomedical research for its potent immunomodulatory and anti-inflammatory properties. In preclinical models of colorectal cancer (CRC) and inflammatory bowel disease (IBD), BL23 has demonstrated the ability to protect against intestinal damage and tumor formation. Its mechanism of action involves the modulation of the host's immune system, specifically by promoting a Th17-biased immune response and stimulating the production of regulatory cytokines such as IL-10, IL-17, IL-22, and TGF-β. While primarily studied in academic settings, it represents a candidate for development as a live biotherapeutic product (LBP).
- Other names
- Lacticaseibacillus casei BL23L. casei BL23
02
Targets
IL-6 (Interleukin 6)IL10 (Interleukin-10)TGFB (GARP–latent transforming growth factor beta 1 complex)IL-17A (Interleukin-17A)IL22 (Interleukin 22)
Beyond the preview
Go deeper on lactobacillus casei BL23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus casei BL23.